Literature DB >> 10709097

Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India.

R Ralhan1, S Arora, T K Chattopadhyay, N K Shukla, M Mathur.   

Abstract

Esophageal cancer (EC) in the Indian population presents in advanced stages with poor prognosis and warrants the identification of a non-invasive marker for early detection and better prognostic assessment. We have previously reported high prevalence of p53 protein accumulation in esophageal squamous-cell carcinomas (ESCCs). The present study was designed to determine (i) if esophageal cancer patients elicit a humoral immune response to intra-tumoral p53 protein accumulation and (ii) their relationship with p53 gene mutations. The goal was to compare the cellular events, p53 protein accumulation and gene mutations with the presence of serum anti-p53 antibodies (p53-Abs) and to assess the utility of serological p53-Ab analysis as a surrogate marker for p53 alterations in esophageal cancer. A high prevalence of circulating p53-Abs was observed in 36 of 60 (60%) ESCC patients. In a subset of 44 ESCCs, exons 5-9 of the p53 gene were examined for mutations by PCR and direct sequencing of PCR products. Mutational data have been correlated with p53-Abs and p53 protein accumulation in ESCCs. Circulating p53-Abs in ESCC patients were significantly associated with intra-tumoral p53 protein accumulation (p=0.0005). A strong correlation observed between humoral immune response against p53 protein, missense gene mutations and protein accumulation warrants the application of serological p53-Abs as a non-invasive surrogate marker in screening high-risk populations for early detection of malignancy. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10709097     DOI: 10.1002/(sici)1097-0215(20000315)85:6<791::aid-ijc9>3.0.co;2-k

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

1.  Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.

Authors:  Hiroki Ochiai; Takashi Ohishi; Koji Osumi; Jo Tokuyama; Hidejirou Urakami; Shikou Seki; Atsushi Shimada; Akira Matsui; Yoh Isobe; Yuya Murata; Takashi Endo; Yoshiyuki Ishii; Hirotoshi Hasegawa; Sumio Matsumoto; Yuko Kitagawa
Journal:  Surg Today       Date:  2011-11-11       Impact factor: 2.549

2.  Specific intronic p53 mutation in esophageal squamous cell carcinoma in Southern Thailand.

Authors:  Paramee Thongsuksai; Pleumjit Boonyaphiphat; Puttisak Puttawibul; Wanna Sudhikaran
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

3.  The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.

Authors:  Yukiharu Hiyoshi; Naoya Yoshida; Masayuki Watanabe; Junji Kurashige; Yoshifumi Baba; Yasuo Sakamoto; Hideo Baba
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

Review 4.  A systematic review of humoral immune responses against tumor antigens.

Authors:  Miriam Reuschenbach; Magnus von Knebel Doeberitz; Nicolas Wentzensen
Journal:  Cancer Immunol Immunother       Date:  2009-06-28       Impact factor: 6.968

5.  Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma.

Authors:  Rei Okada; Hideaki Shimada; Yuichiro Otsuka; Masaru Tsuchiya; Jun Ishii; Toshio Katagiri; Tetsuya Maeda; Yoshihisa Kubota; Tetsuo Nemoto; Hironori Kaneko
Journal:  Surg Today       Date:  2017-05-15       Impact factor: 2.549

6.  Detection of serum p53 antibodies from Chinese patients with papillary thyroid carcinoma using phage-SP-ELISA: correlation with clinical parameters.

Authors:  Pengtao Pan; Xiaoyi Han; Fangqian Li; Qingfeng Fu; Xiang Gao; Hui Sun; Li Wang
Journal:  Endocrine       Date:  2014-03-30       Impact factor: 3.633

7.  Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma.

Authors:  S Guan; B Liu; C Zhang; K-H Lee; S Sun; J Wei
Journal:  Clin Transl Oncol       Date:  2013-02-20       Impact factor: 3.405

8.  Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma.

Authors:  Hideaki Shimada; Tooru Shiratori; Akihiko Takeda; Kazuyuki Matsushita; Shinichi Okazumi; Yasunori Akutsu; Hisahiro Matsubara; Fumio Nomura; Takenori Ochiai
Journal:  World J Surg       Date:  2009-02       Impact factor: 3.352

9.  Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.

Authors:  Jun Dong; Bo-hang Zeng; Li-hua Xu; Jun-ye Wang; Man-zhi Li; Mu-sheng Zeng; Wan-li Liu
Journal:  J Transl Med       Date:  2010-09-03       Impact factor: 5.531

10.  Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma.

Authors:  Leiguang Ye; Songlei Guan; Cong Zhang; Kuang-Hui Lee; Shilong Sun; Jun Wei; Baogang Liu
Journal:  Tumour Biol       Date:  2013-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.